Navigation Links
Genisphere Appoints New CEO, Thomas Bliss
Date:6/30/2015

HATFIELD, Pa., June 30, 2015 /PRNewswire/ -- Genisphere announced Tom Bliss has joined the company as CEO to help further develop Genisphere's therapeutics capabilities and portfolio. Mr. Bliss comes with a wealth of partnering experience, having spent much of the last 25 years in leadership positions at biopharmaceutical companies including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started his career in Investment Banking, with a focus on Technology and Biotech Corporate Finance. He graduated from Dartmouth College with a BA in English and Asian Studies (Mandarin), and completed his MBA at The Wharton School, University of Pennsylvania in Finance and Marketing.

Logo - http://photos.prnewswire.com/prnh/20150629/226697LOGO

Tom joins Genisphere as the Company pivots to focus more resources on its emerging therapeutic portfolio, having established its diagnostics business with key strategic partners. "I am excited to start a new challenge with Genisphere, and look forward to working with the team to develop and expand their pharmaceutical collaborations. I know Genisphere has already had substantial success demonstrating our unique 3DNA technology and I'm sure success will accelerate as additional data are generated."  

Dr. Robert Getts, Chief Science Officer, commented, "Tom's wealth of experience and industry knowledge has already made him a key addition to the Genisphere family. Our new innovations led us to look for an experienced leader for our team who will fit in with the company culture, and I'm sure he will make immediate positive contributions." James Kadushin, Chief Operating Officer, said, "I look forward to working with Tom. It is very fortunate that we were able to find someone with deep pharmaceutical development and partnering experience to fulfill this role."

About Genisphere
Genisphere LLC is a targeted drug delivery platform company. Genisphere's platform is a DNA-based nanotechnology called 3DNA®. 3DNA® nanocarriers are used to deliver drugs in a highly targeted manner. Genisphere's technology is IP-protected and fully customizable to deliver a variety of therapeutics including small drugs, biologics, and nucleic acids. 3DNA® nanostructures are composed entirely of DNA, engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks. Genisphere has been leveraging a collaborative model to advance its drug delivery platform, and continues to seek partnerships with biotechnology and pharmaceutical companies that could benefit from the company's platform technology. Genisphere is also advancing its own lead compounds based on the 3DNA® platform. For more information, please visit http://genisphere.com

For more information contact:

Dr. Robert Getts
Genisphere 
215-996-3027
Email


'/>"/>
SOURCE Genisphere LLC
Copyright©2015 PR Newswire.
All rights reserved

Related biology news :

1. Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer
2. MedNet Appoints Clareece West As Chief Operating Officer
3. Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors
4. EyeLock Appoints Roger An Vice President of Global Market Development
5. EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts
6. EyeLock Appoints Darlene Crumbaugh Vice President of Financial Services
7. Techne Corporation Appoints Dr. J. Fernando Bazan As Chief Technology Officer
8. BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA
9. Homeland Security Corporation (HSCC) Appoints New President with Biometrics and Access Control Solutions Expertise and Contacts
10. Neurobiologist Thomas Jessell to receive $500,000 Gruber Neuroscience Prize
11. Its not all wedded bliss: Marital stress linked to depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 30, 2020 , ... ... therapeutics product portfolio with a near term focus on Type 2 diabetes and ... commercialization experience across multiple therapeutic areas and classes. As Chief Commercial Officer, Justin ...
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. ... the global economic downturn will only increase price pressures overall for the industry. The ... value from every product launch is critical. However, history shows that only a third ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical ... and multiple awards for not only the products and treatments developed, but also ... Vivace® Microneedle RF. All the brands built by ABM have received several honors ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... , ... June 30, 2020 ... ... tissue data insights, today announced that the launch of a new ... with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a ...
(Date:6/28/2020)... SILVER SPRING, Md. (PRWEB) , ... June 26, ... ... the leading trade association representing security solutions providers, today announced its strong opposition ... . , The bill would impose a blanket ban on most federal use ...
(Date:6/23/2020)... , ... June 22, 2020 , ... ... glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for ... DRP-104; and, the other profiles the potent, consistent single agent activity in KEAP1 ...
(Date:6/11/2020)... ... 09, 2020 , ... PathSensors Inc., a Baltimore biotechnology company, ... (SBIR) program funded by the National Institute of Food and Agriculture (NIFA) entitled ... project’s goal was to engineer and develop a field-deployable instrument for portable pathogen ...
Breaking Biology Technology: